| |
| HDV |Abstract Library |
 |
| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
| Abstract Details |
 |
|
| |
| |
| |
|
|
| |
Experimental Drugs for the Treatment of Hepatitis D |
|
|
|
|
| |
J Exp Pharmacol. 2021 Apr 16;13:461-468. doi: 10.2147/JEP.S235550.eCollection 2021.
Lisa Sandmann 1, Markus Cornberg 1 2
|
| |
|
|
| |
Author information
- 1Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
- 2Centre for Individualised Infection Medicine (CiiM), Helmholtz Centre for Infection Research, Braunschweig, Germany.
Abstract
Chronic hepatitis D virus infection is the most severe form of viral hepatitis. Antiviral treatment is urgently needed to prevent patients from developing end stage liver disease or hepatocellular carcinoma. Treatment options were limited to off-label use of pegylated interferon alfa until conditional approval of bulevirtide by the EMA (European Medicines Agency) in July 2020. However, several other antiviral compounds are currently investigated and represent promising agents for the treatment of chronic HDV infection.
|
|
|
|
| |
| |
|
| |
|
|
|
|
|
